MilliporeSigma is in the process of adding 160 jobs at its Jaffrey facility as the global life sciences company ramps up production of components used to develop potential Covid-19 treatments and vaccines. The Jaffrey facility primarily makes filtration devices that are used to produce biopharmaceuticals, such as immunotherapies for cancer treatment. These sorts of products are also part of the standard process for making vaccines, said David Poggi, the plant’s director of operations.. The company’s customers are mainly pharmaceutical corporations, and MiliporeSigma is currently supplying more than 45 companies that are working to develop a Covid-19 vaccine.